Ser1794

Site Information
GGDFKPtsPsLPAsK SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 12069630

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 5 )
Disease tissue studied:	lung cancer ( 3 ) , non-small cell lung adenocarcinoma ( 3 )
Relevant cell line - cell type - tissue:	HeLa (cervical) ( 1 ) , liver ( 2 ) , lung ( 3 ) , M059K (glial) ( 5 )

References
1	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
2	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
3	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
4	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
5	Stokes M (2005) CST Curation Set: 992; Year: 2005; Biosample1/Treatment/Isotope: cell line, M059K/UV/L, Biosample2/Treatment/Isotope: cell line, M059K/UV/H; Disease: glioblastoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST] Curated Info